참고문헌
- Burris H, Eckhardt J, Fields S, et al (1993). Phase II trial of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol, 12, 335.
- Cho KH Song YB, Choi IS, et al (2006). A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol, 36, 50-4. https://doi.org/10.1093/jjco/hyi213
- Cobo M, Gutierrez V, Alcaide J, et al (2007). A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced nonsmall- cell lung cancer and good performance status. Lung Cancer, 56, 255-62. https://doi.org/10.1016/j.lungcan.2006.12.013
- Coskun U, Kaya AO, Buyukberber S, et al (2008). Single agent gemcitabine in the second-line treatment of advanced nonsmall cell lung cancer after treatment with taxane + platinum regimens. Med Oncol, 25, 133-6. https://doi.org/10.1007/s12032-007-9005-3
- Crino L, Mosconi AM, Scagliotti GV, et al (1999). Gemcitabine as second-line treatment for advanced non-small-cell lung cancer, A phase II trial. J Clin Oncol, 17, 2081-5. https://doi.org/10.1200/JCO.1999.17.7.2081
- Fossella FV, De Vore R, Kerr RN, et al (2000). Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 18, 2354-62. https://doi.org/10.1200/JCO.2000.18.12.2354
- Fossella FV, Lee JS, Shin DM, et al (1995). Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol, 13, 645-51. https://doi.org/10.1200/JCO.1995.13.3.645
- Gandara DR, Vokes E, Green M, et al (1997). Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer, a confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol, 16, 454a.
- Gillenwater HH, Tynan M, Natoli S, et al (2000). Second-line gemcitabine in refractory stage IV non-small-cell lung cancer, A phase II trial. Clin Lung Cancer, 2, 133-8. https://doi.org/10.3816/CLC.2000.n.026
- Gridelli C, Perrone F, Gallo C, et al (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC), A phase II trial. Anticancer Res, 19, 4535-8.
- Hertel LW, Boder GB, Kroin JS, et al (1990). Evaluation of the antitumor activity of gemcitabine (20, 20-difluoro-20- deoxycytidine). Cancer Res, 50, 4417-22.
- Juergens R, Brahmer J, Ettinger D (2007). Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer, sequence does matter. Cancer Chemother Pharmacol, 59, 621-9. https://doi.org/10.1007/s00280-006-0304-8
- Kosmas C, Tsavaris N, Syrigos K, et al (2007). A phase I-II study of bi-weekly gemcitabine and irinotecan as secondline chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol, 59, 51-9.
- Lara PN Jr, Gumerlock PH, Mack PC, et al (2004). Gemcitabine in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy, A phase II California cancer consortium trial. Clin Lung Cancer, 6, 102-7. https://doi.org/10.3816/CLC.2004.n.023
- Le Chevalier T. (1995). Docetaxel, meeting the challenge of nonsmall cell lung cancer management. Anticancer Drugs, 6, 13-7. https://doi.org/10.1097/00001813-199507004-00003
- Lund B, Kristjansen PEG, Hansen HH (1993). Clinical and preclinical activity of 20,20-difluoro-20- difluorodeoxycytidine (gemcitabine). Cancer Treat Rev, 19, 45-55.
-
Mattson K, Le Chevalier T, Stupp R, et al (1996). Preliminary report of Phase II study of docetaxel (
$Taxotere^{(R)}$ ) in locally advanced or metastatic non-small cell lung cancer. Ann Oncol, 7, 429a. - Robinet G, Kleisbaurer JP, Thomas P, et al (1996). Phase II study of Taxotere (docetaxel) in advanced or metastatic non-small cell lung cancer previously treated with platinum. Ann Oncol, 7, 96-7. https://doi.org/10.1093/annonc/7.suppl_3.96
- Robinet G, Kleisbaurer JP, Thomas P, et al (1997). Phase II study of docetaxel (Taxotere) in first and second-line NSCLC. Proc Am Soc Clin Oncol, 16, 480.
- Sculier JP, Lafitte JJ, Berghmans T, et al (2000). A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. Lung Cancer, 29, 67-73.
- Shepherd F, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103. https://doi.org/10.1200/JCO.2000.18.10.2095
- Van Kooten M, Traine G, Cinat G, et al (1999). Single agent gemcitabine in pretreated patients with non-small-cell lung cancer, results of an Argentinean multicentre phase II trial. Br J Cancer, 81, 846-9. https://doi.org/10.1038/sj.bjc.6690774
- van Putten JW, Baas P, Codrington H (2001). Activity of singleagent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer, 33, 289-98. https://doi.org/10.1016/S0169-5002(01)00188-X
- Yokoyama A, Kurita Y, Watanabe K (1994). Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer, docetaxel cooperative study group for lung cancer. Gan To Kagaku Ryoho, 21, 2609-16.
피인용 문헌
- Cationic Supramolecular Vesicular Aggregates for Pulmonary Tissue Selective Delivery in Anticancer Therapy vol.11, pp.16, 2016, https://doi.org/10.1002/cmdc.201600070